Viking Therapeutics Inc

Viking Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809 an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß) which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis as well as NAFLD. It also develops VK5211 an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612 an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735 a novel dual agonist of the glucagon-like peptide which is in Phase 1 SAD/MAD clinical trial and VK0214 an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego California.